Under terms of the agreement Regenesis will provide its specialized sales force to market Advanced BioHealing’s product Dermagraft within the Veteran’s Administration (VA), Department of Defense (DOD), and TriCare healthcare payer systems.
Dermagraft is a bioengineered tissue product approved by the FDA for the treatment of diabetic foot ulcers.
Kevin Rakin, chairman and CEO of Advanced BioHealing, said: “The management team at Regenesis has developed a corporate competency in promoting and distributing advanced wound care technology within these systems. We believe this co-promotion is the most effective way to maximize reach and penetration of Dermagraft in this specialized market.”